Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;51(9):3449-51.
doi: 10.1128/AAC.01586-06. Epub 2007 Jun 18.

Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo

Johan W Mouton  1 , Nieko Punt, Alexander A Vinks
Affiliations

Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo

Johan W Mouton et al. Antimicrob Agents Chemother. 2007 Sep.

Abstract

Growth-kill dynamics were characterized in vitro, and the parameter estimates were used to simulate bacterial growth and kill in vivo using both mouse and human pharmacokinetics. The parameter estimates obtained in vitro predicted a time above the MIC of between 35 and 38% for a static effect in mice after 24 h of treatment.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Relationship between kill rates of P. aeruginosa ATCC 27853 and increasing concentrations of ceftazidime.
FIG. 2.
FIG. 2.
Relationship between the dose and ΔCFU for different dosing frequencies after 24 h of treatment using mouse pharmacokinetics (a) and human pharmacokinetics (b). The intersections with the horizontal line (representing no net change in CFU after 24 h of exposure) correspond to the dosing regimens that result in an in vivo static effect.
See this image and copyright information in PMC

References

    1. Andes, D., and W. A. Craig. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268. - PubMed
    1. Bouvier d'Yvoire, M. J. Y., and P. H. Maire. 1996. Dosageregimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin. Drug Investig. 11:229-239.
    1. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501. - PubMed
    1. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12. - PubMed
    1. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292. - PubMed